Magenta Therapeutics, Inc. $69 Million Follow-On Offering of Common Stock
6/29/2020

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics, Inc., including the full exercise of the underwriters’ option to purchase additional common stock. Magenta Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol “MGTA.”

Headquartered in Cambridge, Massachusetts, Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines with the aim of bringing the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associates Scott A. Blumenkranz, Ariel Rivera and Yuchen Han. Partner David R. Bauer and associate Jesse L. Hallock provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Tomislava Dragicevic. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York and Northern California offices.